12:00 AM
 | 
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Huntexil pridopidine: Extension study data

Data from the 6-month, open-label extension of the double-blind, placebo-controlled, European Phase III MermaiHD trial in 353 patients showed that 45 mg twice-daily Huntexil was well tolerated over 12 months with no clinically meaningful changes in vital signs or ECG measurements observed. The most common adverse events were...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >